Targeted Therapy: Precision Medicine for Cancer

Targeted therapy represents a class of cancer treatments that interfere with specific molecular alterations driving tumor growth, distinguishing it mechanistically from conventional chemotherapy. This page covers how targeted agents work, the molecular and genetic contexts in which they apply, the major drug classes and their classification boundaries, and the regulatory framework governing their approval and use. Understanding these distinctions is essential for interpreting treatment plans, molecular profiling and biomarker results, and clinical trial eligibility.

Definition and Scope

Targeted therapy refers to drugs or biologics designed to interact with defined molecular targets — proteins, enzymes, or receptors — that are aberrantly expressed or mutated in cancer cells. The U.S. Food and Drug Administration (FDA) approves targeted agents through its Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), with many approvals contingent on companion diagnostic tests that identify patients whose tumors carry the relevant biomarker (FDA Oncology Center of Excellence).

The scope of targeted therapy has expanded substantially since imatinib (Gleevec) received FDA approval in 2001 for BCR-ABL–positive chronic myeloid leukemia — a milestone frequently cited by the National Cancer Institute as the prototype for molecularly targeted oncology (NCI Dictionary of Cancer Terms). As of the FDA's Hematology/Oncology Approvals database, more than 80 distinct targeted agents are listed across approved oncology indications, addressing tumor types ranging from non-small cell lung cancer to breast cancer, leukemia, and thyroid cancer.

Targeted therapy is distinct from immunotherapy, which mobilizes the immune system broadly or checkpoint-specifically. It is also distinct from hormone therapy for cancer, which manipulates endocrine signaling rather than intracellular kinase cascades or receptor tyrosine kinases directly.

How It Works

Targeted drugs operate by one of two primary mechanisms: signal transduction inhibition or direct molecular disruption. The distinction matters clinically because it determines which biomarker tests are required before treatment initiation.

Signal transduction inhibitors block enzymes — most commonly kinases — that relay growth signals from the cell surface to the nucleus. Tyrosine kinase inhibitors (TKIs) such as erlotinib and osimertinib block EGFR-mutated signaling pathways in non-small cell lung cancer. The kinase cascade involves:

  1. A ligand binding to a transmembrane receptor (e.g., EGFR, HER2, VEGFR)
  2. Receptor dimerization and autophosphorylation at the intracellular kinase domain
  3. Downstream activation of RAS/MAPK or PI3K/AKT/mTOR pathways
  4. Transcription of genes promoting cell cycle progression, survival, and angiogenesis

A small-molecule TKI inserts into the ATP-binding pocket of the kinase domain, competitively blocking phosphorylation and halting the cascade. Resistance commonly develops when secondary mutations (e.g., EGFR T790M) alter the binding pocket structure, which is why third-generation TKIs like osimertinib were developed specifically to overcome T790M resistance (FDA drug approval history for osimertinib, NDA 208065).

Monoclonal antibody-based targeted agents (the "-mab" suffix drugs) bind extracellular receptor domains or circulating ligands. Trastuzumab targets the extracellular domain of HER2, which is overexpressed in approximately 15–20% of breast cancers (National Cancer Institute, Breast Cancer Treatment PDQ). Bevacizumab targets VEGF-A, starving tumors of angiogenic signaling.

Antibody-drug conjugates (ADCs) combine a monoclonal antibody with a cytotoxic payload, delivering chemotherapy directly to antigen-expressing tumor cells while limiting systemic exposure. Ado-trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan are FDA-approved ADCs for HER2-positive breast cancer.

Common Scenarios

Targeted therapy appears across the full oncology landscape. The three most clinically prevalent contexts are:

EGFR-mutated non-small cell lung cancer (NSCLC): EGFR mutations occur in approximately 15% of NSCLC cases in the United States, and a higher proportion in East Asian patient populations (NCI Cancer Stat Facts: Lung and Bronchus). First-line treatment with osimertinib, an FDA-approved third-generation EGFR TKI, is guided by molecular testing of tumor tissue or liquid biopsy.

HER2-positive breast cancer: Trastuzumab-based regimens have been standard since the early 2000s. Pertuzumab, neratinib, and lapatinib extend the HER2-targeted armamentarium. Companion diagnostic testing for HER2 amplification or overexpression — by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) — is required before initiating these agents.

BCR-ABL–positive chronic myeloid leukemia (CML): TKIs remain the backbone of CML management. Second-generation agents (dasatinib, nilotinib) and third-generation agents (ponatinib) address resistance to imatinib. Treatment decisions are guided by BCR-ABL transcript quantification by PCR, monitored per European LeukemiaNet (ELN) response criteria (ELN Recommendations 2020).

BRAF V600E–mutated melanoma, RET-altered thyroid cancer, and ALK-rearranged NSCLC are additional well-characterized scenarios where a single molecular alteration dictates a specific targeted agent class.

Decision Boundaries

Targeted therapy is not universally applicable. Eligibility depends on a confirmed biomarker match between the patient's tumor molecular profile and the drug's mechanism. The regulatory context for oncology establishes that FDA companion diagnostics must meet 510(k) or PMA clearance standards to be used in treatment selection decisions.

Targeted therapy contrasts with chemotherapy along four axes:

Feature Targeted Therapy Chemotherapy
Mechanism Molecularly specific Broad cytotoxicity
Biomarker requirement Usually required Generally not required
Resistance pattern Specific mutation-driven Multifactorial
Toxicity profile Target-mediated (on-target/off-target) Organ-system toxicity

The oncologyauthority.com overview covers the full range of treatment modalities, including contexts where targeted therapy is combined with other approaches.

Key decision limits include:

  1. Absence of a driver mutation — tumors lacking the relevant molecular alteration do not benefit from pathway-specific inhibitors and may be harmed by off-target effects.
  2. Acquired resistance — resistance mechanisms require repeat molecular profiling, as outlined in National Comprehensive Cancer Network (NCCN) guidelines for re-biopsy at progression.
  3. Drug-drug interactions — many TKIs are CYP3A4 substrates; concurrent use of strong CYP3A4 inducers or inhibitors alters drug plasma concentrations materially.
  4. Organ function thresholds — hepatic impairment affects metabolism of most small-molecule TKIs; renal impairment affects antibody clearance for larger biologics.
  5. Brain metastasis penetration — CNS penetration varies substantially by agent; osimertinib demonstrates superior CNS activity compared to first-generation EGFR TKIs, a factor explicitly addressed in FDA labeling.

Safety classification of targeted agents follows FDA labeling categories and CTCAE (Common Terminology Criteria for Adverse Events) grading, maintained by the NCI (CTCAE v5.0, NCI DCTD). Cardiotoxicity (particularly with HER2-directed agents), hepatotoxicity, interstitial lung disease, and QTc prolongation are monitored through structured adverse event grading rather than informal clinical assessment.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)